Grant: Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research
University of Toronto
$250,000.00
Testing the ability of a microbiome-focused intervention to reduce HIV susceptibility in Ugandan men
FY 2016-17
Summary
The foreskin is the site for most HIV acquisition in uncircumcised heterosexual men, but there are many cultural and practical barriers to rolling out penile circumcision for HIV prevention. Over the past five years our unique collaboration has brought together clinicians, epidemiologists and immunologists from East Africa and North America to better understand the immunopathogenesis of HIV acquisition in the foreskin. We have developed new molecular tools to directly quantify HIV susceptibility at this site, and have found that the types of bacteria found under the foreskin (known as the foreskin "microbiome") are a key determinant of HIV acquisition risk, likely because certain bacteria change local immune parameters and recruit particularly HIV-susceptible cells to the place where men are exposed to the virus during sex. In conjunction with our partners at the International AIDS Vaccine Initiative - Uganda Virus Research Institute (IAVI-UVRI), we now propose to use this knowledge in order to test a new way to reduce HIV risk in uncircumcised Ugandan men recruited through the Entebbe General Hospital, Uganda. This trial will (1) establish the impact of two different topical antibiotics on immunology and HIV susceptibility in the foreskin, and (2) assess any impact on mucosal immunology or HIV susceptibility in their female sexual partners. Interventions will consist of two topical antibiotics often used to treat bacterial vaginosis in women, metronidazole and clindamycin, both of which target pro-inflammatory anaerobic bacteria. This work will use state-of-the-art immunologic and molecular tools to define novel, low-tech clinical tools for HIV prevention in Ugandan men, a population where additional prevention tools are badly needed.
Department
Program
Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
350744
Name
Kaul Rupert
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Innovative Biomedical and Clinical HIV/AIDS Research
Projecttitle
Testing the ability of a microbiome-focused intervention to reduce HIV susceptibility in Ugandan men
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$250,000
Cihrequipment2
$0
Programname2
Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research
Keyworddelim
Female Genital Tract; Foreskin; Hiv Susceptibility; International Health; Microbiome; Mucosal Immunology; Topical Antibiotics
Abstract
The foreskin is the site for most HIV acquisition in uncircumcised heterosexual men, but there are many cultural and practical barriers to rolling out penile circumcision for HIV prevention. Over the past five years our unique collaboration has brought together clinicians, epidemiologists and immunologists from East Africa and North America to better understand the immunopathogenesis of HIV acquisition in the foreskin. We have developed new molecular tools to directly quantify HIV susceptibility at this site, and have found that the types of bacteria found under the foreskin (known as the foreskin "microbiome") are a key determinant of HIV acquisition risk, likely because certain bacteria change local immune parameters and recruit particularly HIV-susceptible cells to the place where men are exposed to the virus during sex. In conjunction with our partners at the International AIDS Vaccine Initiative - Uganda Virus Research Institute (IAVI-UVRI), we now propose to use this knowledge in order to test a new way to reduce HIV risk in uncircumcised Ugandan men recruited through the Entebbe General Hospital, Uganda. This trial will (1) establish the impact of two different topical antibiotics on immunology and HIV susceptibility in the foreskin, and (2) assess any impact on mucosal immunology or HIV susceptibility in their female sexual partners. Interventions will consist of two topical antibiotics often used to treat bacterial vaginosis in women, metronidazole and clindamycin, both of which target pro-inflammatory anaerobic bacteria. This work will use state-of-the-art immunologic and molecular tools to define novel, low-tech clinical tools for HIV prevention in Ugandan men, a population where additional prevention tools are badly needed.
Competitiondate
201606
Approvedterm2
1 yr 6 mths
Pinamesdelim
Kaul, Rupert; Coburn, Bryan A; Kiwanuka, Noah
Approvedterm
1 an 6 mois
Cihrcontribution2
~ $250,000~ $0~